

+++ Press Release +++

First treatment with Q-PRO® and integrated BiopSee® image management technology

Darmstadt, Germany 15th of December 2022 - The first treatment combining SpectraCure's next-generation Q-PRO® treatment system and integrated BiopSee® image management technology from MedCom was recently performed at Memorial Sloan Kettering Cancer Center in New York City.

The new generation of SpectraCure's Q-PRO® treatment system, combined with MedCom's BiopSee® ultrasound image management technology, has been FDA-approved for use in a clinical trial for the treatment of prostate cancer recurrence. The first treatment has been carried out at Memorial Sloan Kettering Cancer Center in New York. The process went according to plan and the system met the high expectations very well.

"It is significant that we have now completed the integration of the two technologies and are in the process of improving the accuracy of overall treatment using BiopSee® image management for planning & inserting optical fibers into the prostate together with Q-PRO® laser delivery. In addition, it is very satisfying that we are now receiving concrete proof of the benefits of the integrated approach," says MedCom's CEO Georgios Sakas.

Image-guided photodynamic prostate treatment is becoming a new approach enhancing the existing possibilities in prostate cancer treatment. The improved integrated system means an advantage and simplification for doctors and patients alike. The software has new graphical aids on the screen that make the process faster, intuitive, and more accurate.

- End of Press Release -

About MedCom

MedCom was founded in 1997 and is specialized in the field of medical imaging. As an OEM/B2B company, MedCom is providing products for various global corporations offering integrated clinical solutions, as well as to high-end clinics in the research sector. MedCom offers innovative and advanced imaging-based products with an emphasis on interventional/surgical navigation and cancer treatment solutions (instrument navigation, brachytherapy, patient positioning & verification, and virtual simulation). Among other innovations, MedCom developed the first commercially released "fusion imaging" & navigation product for the liver (2002) and prostate (2007). For more information about MedCom GmbH, please visit www.medcom-online.de